Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

274.48 

-0.89 -0.3%

as of Sep 18 '20

52 Week Range:

219.75 374.99


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 22.64
22.44
25.73
29.43
34.38
44.46
48.37
56.13
60.81
69.81
80.34
growth rate -0.9% 14.7% 14.4% 16.8% 29.3% 8.8% 16.0% 8.3% 14.8% 15.1%
Earnings BIT 1,330.00
1,230.00
1,710.00
1,860.00
2,480.00
3,967.70
5,014.90
5,708.80
5,886.30
6,364.10
7,275.20
growth rate -7.5% 39.0% 8.8% 33.3% 60.0% 26.4% 13.8% 3.1% 8.1% 14.3%
Avg.PE 15.97
17.01
21.83
25.45
35.71
32.50
17.20
16.23
28.84
15.33
10.09
growth rate 6.5% 28.3% 16.6% 40.3% -9.0% -47.1% -5.6% 77.7% -46.8% -34.2%
ROA 11.39
12.08
14.40
14.39
16.94
22.42
20.97
17.47
10.91
18.11
22.42
growth rate 6.1% 19.2% -0.1% 17.7% 32.4% -6.5% -16.7% -37.6% 66.0% 23.8%
ROE 16.13
17.31
20.88
20.62
23.90
30.21
35.15
34.42
20.52
34.54
44.64
growth rate 7.3% 20.6% -1.3% 15.9% 26.4% 16.4% -2.1% -40.4% 68.3% 29.2%
ROIC 13.49
14.59
17.67
17.77
21.71
28.60
26.40
22.28
14.20
23.97
29.59
growth rate 8.2% 21.1% 0.6% 22.2% 31.7% -7.7% -15.6% -36.3% 68.8% 23.5%
Cur. Ratio 3.47
2.42
3.26
1.96
1.81
2.11
2.60
2.55
2.34
2.32
1.72
growth rate -30.3% 34.7% -39.9% -7.7% 16.6% 23.2% -1.9% -8.2% -0.9% -25.9%
Quick Ratio 2.81
1.95
2.74
1.61
1.31
1.54
1.93
1.94
1.78
1.83
1.43
growth rate -30.6% 40.5% -41.2% -18.6% 17.6% 25.3% 0.5% -8.3% 2.8% -21.9%
Leverage 1.37
1.50
1.41
1.46
1.38
1.32
2.08
1.88
1.88
1.94
2.04
growth rate 9.5% -6.0% 3.6% -5.5% -4.4% 57.6% -9.6% 0.0% 3.2% 5.2%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 551.20
605.30
813.33
955.24
1,077.07
1,575.80
1,541.50
1,742.20
2,319.60
2,485.40
2,470.70
growth rate 9.8% 34.4% 17.5% 12.8% 46.3% -2.2% 13.0% 33.1% 7.2% -0.6%
Acct.Payable 909.60
1,204.01
1,754.79
229.20
267.40
279.80
395.50
370.50
530.80
growth rate 32.4% 45.8% -86.9% 16.7% 4.6% 41.4% -6.3% 43.3%
Cur.Assets 2,480.60
2,540.40
2,975.43
3,244.34
3,184.93
4,535.00
6,700.30
8,732.20
7,873.30
7,640.90
8,381.80
growth rate 2.4% 17.1% 9.0% -1.8% 42.4% 47.8% 30.3% -9.8% -3.0% 9.7%
Total Assets 8,551.90
8,092.50
9,049.60
10,130.12
11,863.34
14,314.70
19,504.80
22,876.80
23,652.60
25,288.90
27,234.30
growth rate -5.4% 11.8% 11.9% 17.1% 20.7% 36.3% 17.3% 3.4% 6.9% 7.7%
Cash 581.90
759.60
514.54
570.72
602.56
1,204.90
1,308.00
2,326.50
1,573.80
1,224.60
2,913.70
growth rate 30.5% -32.3% 10.9% 5.6% 100.0% 8.6% 77.9% -32.4% -22.2% 137.9%
Inventory 294.00
289.10
326.84
447.37
659.00
804.00
893.40
1,001.60
902.70
929.90
804.20
growth rate -1.7% 13.1% 36.9% 47.3% 22.0% 11.1% 12.1% -9.9% 3.0% -13.5%
Cur.Liabilities 714.90
1,050.10
912.89
1,657.39
1,758.28
2,218.10
2,577.70
3,419.90
3,368.20
3,295.20
4,863.80
growth rate 46.9% -13.1% 81.6% 6.1% 26.2% 16.2% 32.7% -1.5% -2.2% 47.6%
Liabilities 2,330.30
2,696.00
2,624.11
3,168.60
3,243.09
3,500.70
10,129.90
10,748.20
11,054.50
12,257.30
13,895.20
growth rate 15.7% -2.7% 20.8% 2.4% 7.9% 189.4% 6.1% 2.9% 10.9% 13.4%
LT Debt 1,080.20
1,066.40
1,060.81
687.40
592.43
580.30
6,521.50
6,512.70
5,935.00
5,936.50
4,459.00
growth rate -1.3% -0.5% -35.2% -13.8% -2.1% 1,023.8% -0.1% -8.9% 0.0% -24.9%
Equity 6,221.50
5,396.50
6,425.50
6,961.52
8,620.24
10,809.00
9,372.80
12,140.10
12,612.80
13,039.60
13,343.20
growth rate -13.3% 19.1% 8.3% 23.8% 25.4% -13.3% 29.5% 3.9% 3.4% 2.3%
Common Shares 289.00
255.00
245.00
240.00
238.00
237.00
231.00
219.00
213.00
205.00
187.00
growth rate -11.8% -3.9% -2.0% -0.8% -0.4% -2.5% -5.2% -2.7% -3.8% -8.8%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 165.60
173.10
208.02
254.55
246.30
287.80
643.00
616.10
867.40
770.60
514.50
growth rate 4.5% 20.2% 22.4% -3.2% 16.9% 123.4% -4.2% 40.8% -11.2% -33.2%
Cash Dividends 0.00
23.50
27.10
0.00
0.00
56.10
134.10
134.10
growth rate 15.3% -100.0% 139.0% 0.0%
Cash From OA 1,074.90
1,624.70
1,727.74
1,879.90
2,345.10
2,942.10
3,919.40
4,587.20
4,551.00
6,187.70
7,078.60
growth rate 51.2% 6.3% 8.8% 24.8% 25.5% 33.2% 17.0% -0.8% 36.0% 14.4%
FCF per Share 3.14
5.70
5.95
6.75
-6.38
11.03
12.95
14.85
12.60
23.31
33.09
growth rate 81.5% 4.4% 13.5% -100.0% 100.0% 17.4% 14.7% -15.2% 85.0% 42.0%
Sale Purchase of Stock -331.59
-917.22
-333.50
54.90
-5,000.00
-1,000.00
-1,668.10
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0%
FCF 909.00
1,452.00
1,476.00
1,619.00
-1,164.00
2,654.00
3,073.00
3,794.00
2,588.00
5,302.00
6,409.00
growth rate 59.7% 1.7% 9.7% -100.0% 100.0% 15.8% 23.5% -31.8% 104.9% 20.9%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 4,377.30
4,716.40
5,048.63
5,516.46
6,932.20
9,703.30
10,763.80
11,448.80
12,273.90
13,452.90
14,377.90
growth rate 7.8% 7.0% 9.3% 25.7% 40.0% 10.9% 6.4% 7.2% 9.6% 6.9%
Op.Income 1,295.40
1,248.90
1,234.43
1,426.83
1,887.30
3,967.70
5,014.90
5,708.80
5,886.30
6,364.10
7,275.20
growth rate -3.6% -1.2% 15.6% 32.3% 110.2% 26.4% 13.8% 3.1% 8.1% 14.3%
IBT 1,332.70
1,229.90
1,711.21
1,901.90
2,505.50
3,931.50
4,754.80
4,933.00
5,128.80
5,899.60
7,046.50
growth rate -7.7% 39.1% 11.1% 31.7% 56.9% 20.9% 3.8% 4.0% 15.0% 19.4%
Net Income 970.10
1,005.30
1,234.43
1,426.83
1,887.30
2,934.80
3,547.00
3,702.80
2,539.10
4,430.70
5,888.50
growth rate 3.6% 22.8% 15.6% 32.3% 55.5% 20.9% 4.4% -31.4% 74.5% 32.9%
EPS 3.35
3.94
5.04
5.76
7.81
12.37
15.34
16.93
11.92
21.58
31.42
growth rate 17.6% 27.9% 14.3% 35.6% 58.4% 24.0% 10.4% -29.6% 81.0% 45.6%
Gross Profit 3,995.20
4,316.20
4,581.85
4,970.97
6,074.50
8,532.30
9,523.40
10,015.60
10,643.90
11,636.60
12,422.50
growth rate 8.0% 6.2% 8.5% 22.2% 40.5% 11.6% 5.2% 6.3% 9.3% 6.8%
R&D 1,283.10
1,248.60
1,219.60
1,334.92
1,444.10
1,893.40
2,012.80
1,973.30
2,253.60
2,597.20
2,264.90
growth rate -2.7% -2.3% 9.5% 8.2% 31.1% 6.3% -2.0% 14.2% 15.3% -12.8%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 1,975.60
1,947.00
1,722.50
1,890.30
1,998.50
growth rate -1.5% -11.5% 9.7% 5.7%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 2,517.10
2,515.80
2,470.70
2,604.20
2,574.70
growth rate -0.1% -1.8% 5.4% -1.1%
Acct.Payable 377.10
382.20
530.80
389.00
383.90
growth rate 1.4% 38.9% -26.7% -1.3%
Cur.Assets 7,909.80
8,448.20
8,381.80
8,007.20
8,493.80
growth rate 6.8% -0.8% -4.5% 6.1%
Total Assets 26,287.60
27,484.00
27,234.30
26,119.20
25,511.80
growth rate 4.6% -0.9% -4.1% -2.3%
Cash 1,723.40
2,343.90
2,913.70
2,591.30
2,384.90
growth rate 36.0% 24.3% -11.1% -8.0%
Inventory 776.70
751.80
804.20
858.80
952.70
growth rate -3.2% 7.0% 6.8% 10.9%
Cur.Liabilities 3,210.90
4,432.20
4,863.80
4,638.60
3,447.10
growth rate 38.0% 9.7% -4.6% -25.7%
Liabilities 13,338.80
13,492.20
13,895.20
13,582.30
14,222.60
growth rate 1.2% 3.0% -2.3% 4.7%
LT Debt 5,948.50
4,458.20
4,459.00
4,459.90
7,423.80
growth rate -25.1% 0.0% 0.0% 66.5%
Equity 12,952.90
13,995.90
13,343.20
12,546.90
11,308.70
growth rate 8.1% -4.7% -6.0% -9.9%
Common Shares 0.10
0.10
0.10
0.10
0.10
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 186.90
90.10
110.40
149.70
105.00
growth rate -51.8% 22.5% 35.6% -29.9%
Cash Dividends
growth rate
Cash From OA 1,964.00
1,694.90
1,960.20
1,467.30
1,948.50
growth rate -13.7% 15.7% -25.2% 32.8%
Sale Purchase of Stock
growth rate
FCF 1,777.10
1,604.80
1,849.80
1,317.60
1,843.50
growth rate -9.7% 15.3% -28.8% 39.9%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 3,616.70
3,600.10
3,671.30
3,534.30
3,681.60
growth rate -0.5% 2.0% -3.7% 4.2%
Op.Income 1,975.60
1,947.00
1,722.50
1,890.30
1,998.50
growth rate -1.5% -11.5% 9.7% 5.7%
IBT 1,742.20
1,757.20
1,715.80
1,684.60
2,052.60
growth rate 0.9% -2.4% -1.8% 21.8%
Net Income 1,494.10
1,545.90
1,439.70
1,399.10
1,542.10
growth rate 3.5% -6.9% -2.8% 10.2%
EPS
growth rate
Gross Profit 3,140.40
3,170.10
3,224.20
3,080.00
3,270.50
growth rate 1.0% 1.7% -4.5% 6.2%
R&D 473.60
538.60
689.30
476.30
647.60
growth rate 13.7% 28.0% -30.9% 36.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (87.23)

YOY Growth Grade:

B (69.56)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 8.24 8.06 9.00
EPS / Growth 16.9% 34.04 -0.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 6.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 3.9% 3.9%
Future PE 2.00 8.32 8.32
Future EPS 37.61 49.72 49.72
Value Price
MOS %
18.59
-93.2%
102.27
-62.7%
102.27
-62.7%
MOS Price 9.30 51.13 51.13
IRT 7.72 6.92 6.92

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.